Skip to main content

Table 1 Ongoing clinical trial of oncolytic adenovirus. The virus name and fiber modifications employed for enhancing internalization of various oncolytic adenovirus are presented

From: Overcoming the limitations of locally administered oncolytic virotherapy

Trial ID Phase Disease Condition Oncolytic adenovirus Fiber modification Internalization mechanism Administration Route Monotherapy/Combination therapy
NCT03029871 I Lung cancer Ad5-yCD/mutTKSR39rep-ADP None Coxsackie and adenovirus receptor (CAR) Local delivery Combination therapy
NCT02555397 I Prostate cancer Ad5-yCD/mutTKSR39rep-hIL12 None CAR Local delivery Monotherapy
NCT03281382 I Pancreatic cancer Ad5-yCD/mutTKSR39rep-hIL12 None CAR Local delivery Combination therapy
NCT03190824 II Skin cancer OBP-301 None CAR Local delivery Monotherapy
NCT02045602 I Multiple cancer types VCN-01 replacement of the heparan sulfate glycosaminoglycan putative-binding site KKTK of the fiber shaft with an integrin-binding motif RGDK for tumor targeting Integrin Systemic delivery Combination therapy
NCT03799744 I Head and neck cancer VCN-01 replacement of the heparan sulfate glycosaminoglycan putative-binding site KKTK of the fiber shaft with an integrin-binding motif RGDK for tumor targeting Integrin Systemic delivery Combination therapy
NCT03225989 I/II Multiple cancer types LOAd703 Serotype 35 adenovirus fiber CD46 Local delivery Combination therapy
NCT02705196 I/II Pancreatic cancer LOAd703 Serotype 35 adenovirus fiber CD46 Local delivery Combination therapy
NCT03003676 I Skin cancer ONCOS-102 serotype 5/3 capsid-modified adenovirus Desmoglein 2 Local delivery Combination therapy
NCT03514836 I/II Prostate cancer ONCOS-102 serotype 5/3 capsid-modified adenovirus Desmoglein 2 Local delivery Combination therapy
NCT02879669 I/II Pleural mesothelioma ONCOS-102 serotype 5/3 capsid-modified adenovirus Desmoglein 2 Local delivery Combination therapy
NCT03852511 I Multiple cancer types NG-350A group B Ad11p/Ad3 chimeric adenovirus Desmoglein 2 Local & Systemic delivery Monotherapy
NCT03714334 I Brain cancer DNX-2440 insertion of integrin binding RGD-4C motif for tumor targeting in fiber domain Integrin Local delivery Monotherapy
NCT03178032 I Brain cancer DNX-2401 insertion of integrin binding RGD-4C motif for tumor targeting in fiber domain Integrin Local delivery Monotherapy
NCT02798406 II Brain cancer DNX-2401 insertion of integrin binding RGD-4C motif for tumor targeting in fiber domain Integrin Local delivery Combination therapy
NCT03896568 I Brain cancer BM-Ad5-DNX-2401(DNX-2401 loaded into mesenchymal stem cell) insertion of integrin binding RGD-4C motif for tumor targeting in fiber domain Integrin Systemic delivery Combination therapy
NCT03072134 I Brain cancer NSC-CRAd-Survivin-pk7(Neural stem cells loaded with CRAd-Survivin-pk7) fiber protein polylysine modification (pk7) for enhanced cell internalization Nonspecific enhancement in cell uptake through increased cationic charge (polylysine) Local delivery Combination therapy